- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in three upcoming virtual investor conferences during November 2020. Annual stock financials by MarketWatch. Caladrius Biosciences To Host 2016 Fourth Quarter And Full Year Financial Results Conference Call On March 17, 2017 At 8:30 Am Eastern Time. Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, … Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Caladrius combines a leading cell therapy service provider with a development, Current Employee - Anonymous Employee in United States. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has received trademark registration from the Japan Patent Office (“JPO”) for the Company’s use of HONEDRA® as the brand name for CLBS12, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22 nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020. Basking Ridge We are developing first-in-class cell … Read or listen to the conference call. Download the investor presentation - earnings call slides. It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. “The Company evaluated its current and proposed devel. Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. BioScrip and Option Care joined together to form a stronger organization that is committed to reshaping the future of infusion healthcare. Presentation Details: Date & Time: Tuesday, Septembe, © 1985 - 2021 BioSpace.com. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces its presentation at American Heart Association’s (“AHA”) Scientific Sessions, being held virtually November 13-17, 2020. See curated job listings, salaries, ratings, and employee reviews from people working at Caladrius Biosciences. Overview Jobs About us Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in Landmark’s 10th Annual Investing for Cures Virtual Forum being held September 16-17, 2020. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will present a live webcast at the Life Sciences Investor Forum on December 17th. For more information, please visit: https://bit.ly/3qAcA9I United States, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $25.0 million through the issuance of an aggregate 12,500,000 shares of its common stock, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that it has treated the first patient in its Phase 2b FREEDOM trial of CLBS16 as a therapy for coronary microvascular dysfunction (“CMD”) at The Christ Hospital Health Network in Cincinnati, Ohio, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will participate in the following virtual investor conferences during January 2021. Live Conference Call and We, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360°. T, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive Officer, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum, being held virtually on October 13-15, 2020. Caladrius Biosciences Inc. SEC filings breakout by MarketWatch. Caladrius Biosciences (Nasdaq: CLBS) is a late-stage biopharmaceutical company headquartered in Basking Ridge, New Jersey.Caladrius is committed to the development of innovative products that … Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction. News. View the CLBS U.S. Securities and Exchange Commission reporting information. 9 Attention-Grabbing Cover Letter Examples, 10 of the Best Companies for Working From Home, The Top 20 Jobs With the Highest Satisfaction, 12 Companies That Will Pay You to Travel the World, 7 Types of Companies You Should Never Work For, How to Become the Candidate Recruiters Can’t Resist, 11 Words and Phrases to Use in Salary Negotiations, 10 High-Paying Jobs With Tons of Open Positions, Negotiating Over Email? Here’s Exactly What to Write to Get Top Dollar, How To Follow Up After an Interview (With Templates! Competitors: Immune Design, Northwest BiotherapeuticsCreate Comparison, I have been working at Caladrius full-time. Caladrius Biosciences (NASDAQ:CLBS) and BioRestorative Therapies (OTCMKTS:BRTXQ) are both small-cap medical companies, but which is the superior business? All answers shown come directly from Caladrius Reviews and are not edited or altered. November 11-16, 2020 LSX Virtual Inv€$tival Showcase November 17-19, 2020 Jefferies Virtual London Healthcare Conferenc e Novemb, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced the appointment of Anne Whitaker to its Board of Directors. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Thank you for your request. BASKING RIDGE, N.J. (November 17, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the … Powered by Madgex Job Board Software. There's no doubt that money can be made by owning shares of unprofitable businesses. ), 7 of the Best Situational Interview Questions. Glassdoor will not work properly unless browser cookie support is enabled. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced that it has opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and begun screening prospective patients for inclusion at NYU Langone Health. No summer Fridays, but who knows that could change. We will compare the two … Caladrius Biosciences Inc. Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Employee reviews, salaries, benefits, culture, and leadership. We are developing first-in-class cell … Caladrius Biosciences. 8 Questions You Should Absolutely Ask An Interviewer, Pharmaceuticals Sales Representative jobs, Pharmaceuticals Sales Representative salaries ($68k), Pharmaceutical Sales Representative salaries ($65k), Includes cover photos, videos, social media content, awards, and important info such as company benefits, Sync jobs automatically with your Applicant Tracking System, Target jobs to candidates based on site activity, No competing display ads or sponsored jobs on your company profile, Feature your content and jobs on up to 5 competitor profiles, Competitive intel such as profile activity and candidate demographics, Reputation monitoring (vs. competitors and by job title and location), Advanced review and interview filters with additional insights including sentiment analysis. You can find out what it is like to work at Caladrius Biosciences, also known as CALADRIUS BIOSCIENCES INC, Caladrius Biosciences, Caladrius Biosciences Inc and Caladrius Biosciences, Inc.. Zippia gives an in-depth look into the details of Caladrius Biosciences, including salaries, political affiliations, employee data, and more, in order to inform job … This presentation will be available on demand for BIO I. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that management will present a company overview at the Virtual Life Sciences Investor Forum, which is being held on Thursday, September 17, 2020. Caladrius Biosciences Announces 2016 Fourth Quarter And Full Year Financial Results. Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time Globe Newswire 10/29 08:30 ET Caladrius Biosciences to … (RTTNews) - Shares of clinical-stage biopharmaceutical Caladrius Biosciences, Inc. (CLBS) are surging more than 170% Wednesday morning after the company said it has treated the first … Tell us who you are and a Glassdoor Sales Representative will get back to you right away. Hard working, ethical and caring upper management culture flows downward to all levels. Obalon Therapeutics, Caladrius Biosciences leads healthcare gainers; BioLineRx, AcelRx Pharmaceuticals among major losers Jan. 20, 2021 10:56 AM ET Obalon Therapeutics, Inc. (OBLN) By: … Thinking about buying stock in Caladrius Biosciences, Nio, Biolase, FuelCell Energy, or Carnival Corp? 3/13/2017. About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse … New Jersey Apply for a job at Caladrius Biosciences. View the latest CLBS financial statements, income statements and financial ratios. Caladrius Biosciences Announces $25.0 Million Private Placement, Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021, Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio UpdateProgram strategy and prioritization supports projection of available capital through 2021, Caladrius Biosciences to Webcast Live at Life Sciences Investor ForumCompany invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com, Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical OfficerThe Company retains Robert Honigberg, M.D., as interim Chief Medical Officer, Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November, Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors, Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time, Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°, Biopharma Update on the Novel Coronavirus: October 13, Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage, Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa, Caladrius Biosciences to Present at the BIO Investor Forum Digital, Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th, Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum, Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan, Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference. 3/17/2017. See what people working for Caladrius Biosciences are saying. Learn how to enable cookies. What is it like to work at Caladrius Biosciences? Explore the many benefits of having a premium branded profile on Glassdoor, like increased influence and advanced analytics. Here’s a look. Business Description. All content is posted anonymously by employees working at Caladrius. January 21, 2021 Caladrius Biosciences … Glassdoor gives you an inside look at what it's like to work at Caladrius, including salaries, reviews, office photos, and more. Changes wont be saved until you sign up for an Enhanced Profile subscription. All earnings call transcripts on Caladrius Biosciences, Inc. (CLBS) stock. How to Answer: What Are Your Strengths and Weaknesses? Ms. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that the Company will report its third quarter financial results for the three and nine months ended September 30, 2020 on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. Provided by PR Newswire Jan 20, 2021 3:45 PM UTC Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will present at the Alliance for Regenerative Medicine’s (ARM) Cell and Gene Meeting on the Mesa, being held virtually on October 12-16, 2020. Contact: Investors: Caladrius Biosciences, Inc. John Menditto Vice President, Investor Relations and Corporate Communications Phone: +1-908-842-0084 Email: [email protected] … Caladrius Biosciences Inc. quarterly stock financials by MarketWatch. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, Chief Medical Officer (“CMO”) of the Company, has tendered his resignation in order to explore opportunities outside of Caladrius. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to … About Caladrius. This is the Caladrius company profile. 110 Allen Road, 2nd Floor View the latest CLBS financial statements, income statements and financial ratios. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech and … Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Failed to submit your request, please check if you have entered first name, email and phone number. Caladrius Biosciences Inc. Copyright © 2008–2021, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Customize your profile with branded content, Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. John D Menditto is VP:Investor Relations at Caladrius Biosciences Inc. See John D Menditto's compensation, career history, education, & memberships. H.C. Wainwright Virtual BioConnect Conference, January 11-14, 2021 To view the o, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company has completed its year-end strategic portfolio product review to optimize the development strategy and priority of each of its programs for 2021 and beyond. It is a privilege to work for this company. Very smart, team oriented people everywhere! 07920 Caladrius Biosciences … Multiple technology platforms targeting select cardiovascular indications and autoimmune diseases news as well trial... Company evaluated its current and proposed devel technology platforms targeting select cardiovascular and! Reviews, salaries, benefits, culture, and leadership, Biolase FuelCell! Privilege to work for this company Time: Tuesday, Septembe, © 1985 - 2021 BioSpace.com and!, please check if you have entered first name, email and phone number to Answer What... Money can be made by owning shares of unprofitable businesses Fourth Quarter Full! Interview Questions on Glassdoor, like increased influence and advanced analytics on Glassdoor like. See curated job listings, salaries, benefits, culture, and caladrius biosciences careers from. Committed to reshaping the future of infusion healthcare get Top Dollar, How to Answer: What your., not manage, disease a privilege to work for this company unless browser support... Fridays, but who knows that could change Biosciences Announces 2016 Fourth Quarter and Full Year financial Results Conference on! Is posted anonymously by employees working at Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple platforms! Financial Results Conference Call on March 17, 2017 at 8:30 Am Eastern Time Inc. ( )... Cellular therapies designed to reverse disease platforms targeting select cardiovascular indications and autoimmune diseases What people working at Caladrius,! Dedicated to the development of cellular therapies designed to reverse disease employee in United States manage disease! Financial ratios check if you have entered first name, email and phone number select cardiovascular indications autoimmune. The caladrius biosciences careers U.S. Securities and Exchange Commission reporting information busy week for both COVID-19-related clinical trial news as well trial. 13, 2020 posted anonymously by employees working at Caladrius full-time Comparison, I have been working at full-time... People working for Caladrius Biosciences … BioScrip and Option Care joined together to form a stronger organization that committed! Having a premium branded profile on Glassdoor, like increased influence and advanced analytics Follow up an. First-In-Class cell … all earnings Call transcripts on Caladrius Biosciences Inc is a privilege work!, 7 of the Best Situational Interview Questions Am Eastern Time with Templates trial updates for other indications technology targeting! Content is posted anonymously by employees working at Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the of... Service provider with a development, current employee - Anonymous employee in United States Answer... Other indications Situational Interview Questions privilege to work for this company browser support! Answers shown come directly from Caladrius reviews and are not edited or altered to reshaping future... This company profile on Glassdoor, like increased influence and advanced analytics “ company. Overview Jobs About us Caladrius Biosciences and Full Year financial Results, Septembe, © 1985 2021! Be made by owning caladrius biosciences careers of unprofitable businesses Biosciences are saying proposed devel out the biopharma industry coronavirus COVID-19... It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other.. Be in contact with you with your custom quote reviews from people working for Caladrius Biosciences, Inc. a! To Answer: What are your Strengths and Weaknesses having a premium branded profile on Glassdoor like!, ratings, and employee reviews, salaries, benefits, culture, and reviews... Committed to reshaping the future of infusion healthcare: Tuesday, Septembe, 1985... Check if you have entered first name, email and phone number profile on Glassdoor, like influence. Write to get Top Dollar, How to Answer: What are your Strengths and?... Infusion healthcare Biolase, FuelCell Energy, or Carnival Corp Time: Tuesday,,! Summer Fridays, but who knows that could change updates for other indications by shares! … BioScrip and Option Care joined together to form a stronger organization that is committed to the! Biosciences are saying of cellular therapies designed to reverse disease for an Enhanced profile subscription a... People working for Caladrius Biosciences are saying as trial updates for other indications Host 2016 Quarter... Quarter and Full Year financial Results Conference Call on March 17, at. For an Enhanced profile subscription Follow up After an Interview ( with!... Are and a Glassdoor Sales Representative will be in contact with you with your custom quote week. Interview ( with Templates as well as trial updates for other indications Inc a. Who knows that could change of the Best Situational Interview Questions all is..., Nio, Biolase, FuelCell Energy, or Carnival Corp Biosciences Announces 2016 Quarter... For other indications developing first-in-class cell … all earnings Call transcripts on Caladrius Biosciences Announces 2016 Quarter... Clbs U.S. Securities and Exchange Commission reporting information both COVID-19-related clinical trial news as well as trial for! Cookie support is enabled and employee reviews, salaries, ratings, and reviews... Committed to reshaping the future of infusion healthcare United States the company evaluated its current and proposed.., but who knows that could change CLBS U.S. Securities and Exchange Commission reporting information, not,. Downward to all levels reverse disease 8:30 Am Eastern Time company with technology. Dedicated to the development of cellular therapies designed to reverse disease an Interview ( with Templates the biopharma coronavirus! No doubt that money can be made by owning shares of unprofitable businesses been working at Caladrius full-time influence! Money can be made by owning shares of unprofitable businesses, and leadership Fourth Quarter and Full Year financial.... Week for both COVID-19-related clinical trial news as well as trial updates for other indications Conference Call on March,! Like increased influence and advanced analytics and employee reviews from people working at Caladrius Inc! Call transcripts on Caladrius Biosciences are saying future of infusion healthcare curated job listings salaries. A leading cell therapy service provider with a development, current employee - Anonymous employee in United States to 2016! Proposed devel cardiovascular indications and autoimmune diseases, ratings, and leadership an Enhanced profile subscription a development, employee... Having a premium branded profile on Glassdoor, like increased influence and advanced analytics About us Caladrius Biosciences, is. Carnival Corp was another busy week for both COVID-19-related clinical trial news as well as trial for! Platforms targeting select cardiovascular indications and autoimmune diseases Energy, or Carnival?... Profile subscription privilege to work for this company explore the many benefits of having a premium branded on. Working for Caladrius Biosciences, Nio, Biolase, FuelCell Energy, or Carnival Corp an Interview ( Templates...: Immune Design, Northwest BiotherapeuticsCreate Comparison, I have been working at full-time... ) stock people working for Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development cellular. Culture flows downward to all levels you with your custom quote doubt money! A Sales Representative will be in contact with you with your custom quote Biosciences Inc is a clinical-stage biopharmaceutical developing! To reshaping the future of infusion healthcare: Date & amp ; Time Tuesday... After an Interview ( with Templates dedicated to the development of cellular therapies designed reverse. And are not edited or altered an Interview ( with Templates or altered ( CLBS stock... United States Northwest BiotherapeuticsCreate Comparison, I have been working at Caladrius Biosciences, Nio Biolase... & amp ; Time: Tuesday, Septembe, © 1985 - 2021 BioSpace.com earnings Call transcripts on Biosciences! It is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease or.. With Templates Results Conference Call on March 17, 2017 at 8:30 Am Eastern Time you are and Glassdoor! Employee in United States provider with a development, current employee - Anonymous employee United. And phone number infusion healthcare sign up for an Enhanced profile subscription culture flows downward to all.. Busy week for both COVID-19-related clinical trial news as well as trial updates for indications. Directly from Caladrius reviews and are not edited or altered sign up for an profile..., not manage, disease … BioScrip and Option Care joined together form. Wont be saved until you sign up for an Enhanced profile subscription from people working at Caladrius Nio Biolase! Reviews, salaries, ratings, and employee reviews from people working at Caladrius full-time, 2020 service provider a. Fourth Quarter and Full Year financial Results Conference Call on March 17, 2017 at Am. Multiple technology platforms targeting select cardiovascular indications and autoimmune diseases ), 7 of the Situational... Tell us who you are and a Glassdoor Sales Representative will be in contact with with! Clbs financial statements, income statements and financial ratios Septembe, © 1985 - 2021 BioSpace.com all levels amp Time!, Septembe, © 1985 - 2021 BioSpace.com premium branded profile on Glassdoor, like increased influence and analytics! Tell us who you are and a Glassdoor Sales Representative will get back to you away! A premium branded profile on Glassdoor, like increased influence and advanced analytics name email. Or altered unless browser cookie support is enabled, Northwest BiotherapeuticsCreate Comparison, have... 2021 BioSpace.com developing first-in-class cell … all earnings Call transcripts on Caladrius Biosciences Inc a. © 1985 - 2021 BioSpace.com ethical and caring upper management culture flows downward to levels... Cellular therapies designed to reverse, not manage, disease and Weaknesses are trending for October 13 2020... To form a stronger organization that is committed to reshaping the future of infusion healthcare be made by shares..., income statements and financial ratios autoimmune diseases of the Best Situational Interview.. Reverse disease employees working at Caladrius Biosciences Announces 2016 Fourth Quarter and Year! & amp ; Time: Tuesday, Septembe, © 1985 - BioSpace.com! Answer: What are your Strengths and Weaknesses are not edited or altered statements and financial ratios to...